Monosaccharide-based Nanoparticle Production Service
Overview of Monosaccharide-based Nanoparticles
Monosaccharide-based nanoparticles are nanoparticles that integrate monosaccharides, such as galactose, on their surface or within their structure, offering a versatile platform for targeted drug delivery and biomedical applications. These nanoparticles are often produced using Various Advanced Techniques, specifically, galactose-modified nanoparticles are frequently produced through galactosylation, thiol–ene reactions, or amide coupling, which allow for precise functionalization of the nanoparticles to enhance targeting and stability.
Fig.1 The schematic diagram of the preparation of GNPs and GAL-PEG-GNPS. (Zhu. et al., 2015)
Our GlycoNano™ Platform offers advanced Glyconanoparticle Development Services and Carbohydrate-based Nanoparticle Production Services. By integrating carbohydrates into nanoparticle structures, our systems are not only biocompatible and biodegradable but also capable of selectively targeting specific cells and tissues.
A key offering under this platform is monosaccharide-based nanoparticle production. This service includes a variety of custom solutions, such as galactose-modified nanoparticles, designed for enhanced targeting and therapeutic efficiency. For example, galactose-modified liposomal nanoparticles, PLGA nanoparticles containing galactose-modified vancomycin, and galactose-modified upconversion nanoparticles. Our service also extends to galactose/chitosan-modified nanoparticles, like galactose-chitosan nanoparticles and galactose-modified 5-fluorouracil nanoparticles, offering tailored solutions for diverse biomedical needs.
| Galactose-modified Nanoparticle Production | |
| Galactosylation-targeted Liposomal Nanoparticles | GSH-responsive PLGA Nanoparticles Containing Galactose-modified Vancomycin |
| ROS-responsive PLGA Nanoparticles Containing Galactose-modified Vancomycin | PLGA Nanoparticles Containing Galactose-modified Vancomycin |
| PLGA Nanoparticles Containing Rapamycin Surface-modified Galactose | Galactose-modified Upconversion Nanoparticles |
| Galactose-mediated Turmeric-Based Bovine Serum Albumin Nanoparticles | Galactose Vinyl Ester Nanoparticles |
| Galactosylated Albumin Magnetic Adriamycin Nanoparticles (Gal-MADM-NP) | Galactose-modified Pea Albumin 1b Nanoparticles |
| Galactose-modified Ricin Nanoparticles | Galactose Conjugated Bean Innocent Protein Nanoparticles |
| Galactose-Myoalbumin Nanoparticle Complex | Galactose Conjugated Wheat Gleysolmin Nanoparticles |
| Galactose-modified Whey Albumin Nanoparticles (Whey Protein-Galactose) | Galactose-modified Rat Serum Albumin Nanoparticles (RSA-Galactose) |
| Galactose-Mouse Serum Albumin Nanoparticle Complex (MSA-Galactose) | Galactose Ova-Galactose Conjugated Ovasmin Nanoparticles (OVA-galactose) |
| Galactose-modified Human Serum Albumin Nanoparticle (HSA-Galactose) | Galactose-modified Bovine Serum Albumin Nanoparticle (BSA-Galactose) |
| Galactose Coupled Tungsten Diselenide Wse2 Nanoparticle (Galactse-Wse2)(Wse2-Galactse) | RNA-loaded Galactose Derivative Cationic Liposome Nanoparticles |
| Galactose-modified Mercaptochitosan Quaternary Ammonium Nanoparticles (Gal-Tmc-Cys) | |
| Galactose/Chitosan-modified Nanoparticle Production | |
| Galactose Chitosan Oligosaccharide Nanoparticles | Norcantharidin-Galactose-modified Chitosan Nanoparticles (Nctd-Gc-Nps) |
| Galactose Chitosan (Gc)/ 5-Aerouracil (5-Fu) Nanoparticles | Galactose Chitosan 5-Fluorouracil Nanoparticles (Gc-5-Fu) |
| Galactosyl Chitosan Nanoparticles | |
Quality Analysis of Monosaccharide-based Nanoparticles
To ensure the quality and performance of monosaccharide-based nanoparticles, several analytical techniques are employed, you can also go to our Glyconanoparticle Characterization Service Section for more comprehensive analysis services.
Zeta Potential Analysis
Assesses the surface charge of nanoparticles to ensure stability and dispersion in biological media.
Dynamic Light Scattering
Measures the size distribution of the nanoparticles.
Transmission Electron Microscopy
Provides detailed images of nanoparticle morphology.
FTIR
Helps confirm the chemical composition and functional groups on the nanoparticle surface.
UV-Vis Spectroscopy
Monitors the absorption of light to evaluate the encapsulation efficiency and release profiles of the nanoparticle.
Applications

Targeted Drug Delivery
Monosaccharide-based nanoparticles are highly effective in the development of targeted drug delivery due to their ability to be specifically designed to bind to receptors on the surfaces of particular cells.

Imaging Applications
In addition to drug delivery, monosaccharide-based nanoparticles are also valuable in the development of imaging applications. These nanoparticles can be loaded with contrast agents, making them ideal for diagnostic purposes.

Therapeutic Interventions
Monosaccharide-based nanoparticles are also pivotal in various developments of therapeutic interventions, particularly in controlled drug release and gene delivery. By modifying the surface properties of the nanoparticles with monosaccharides like galactose, they can be engineered to release therapeutic agents in a controlled manner.
Advantages
- Being derived from natural sugars, these nanoparticles are typically non-toxic and break down safely within the body.
- The modification with specific monosaccharides, like galactose, enhances the ability of these nanoparticles to target specific cells, improving the precision of treatment.
- The surface and structure of monosaccharide-based nanoparticles can be easily modified to suit various biomedical needs.
Frequently Asked Questions
- What is the production scale of monosaccharide-based nanoparticles at CD BioGlyco?
Our monosaccharide-based nanoparticles are produced in a range of scales to meet diverse research needs, from hundreds of milligrams to gram-scale production. This flexibility ensures that we can accommodate both small-scale studies and larger, more extensive research projects. -
What are the applications of monosaccharide-based nanoparticles?
Monosaccharide-based nanoparticles are primarily used for targeted drug delivery, imaging applications, and therapeutic interventions. By modifying nanoparticles with monosaccharides like galactose, they can selectively bind to specific receptors on cancer cells or immune cells, improving drug delivery and reducing side effects.
Publication
Technology: GAL-PEG-GNP synthesis, Dynamic light scattering, UV-Vis spectroscopy, Transmission electron microscopy, Inductively coupled plasma mass spectrometry
Journal: Journal of Nanobiotechnology
IF: 10.6
Published: 2015
Results: This study investigates the use of galactose-functionalized gold nanoparticles (GAL-PEG-GNPs) as a radiosensitizer for enhancing the effectiveness of radiation therapy in hepatocellular carcinoma (HCC) cells. The research demonstrates that GAL-PEG-GNPs are more effectively internalized by HepG2 cells compared to bare GNPs due to their targeting of the asialoglycoprotein receptor (ASGPR) on the cell surface. Upon exposure to X-ray irradiation, GAL-PEG-GNPs significantly enhance DNA damage, cell cycle arrest, and apoptosis in HepG2 cells. The radiosensitization mechanism is attributed to the generation of free radicals, leading to increased oxidative stress and apoptosis-related protein expression.
Fig.2 Characterization of nanoparticles. (a) Shows the appearance of GNPs (left) and GAL-PEG-GNPs (right); (b) Shows the size distribution of GNPs (blue) and GAL-PEG-GNPs (red); (c) Shows absorption peak of GNPs (blue) and GAL-PEG-GNPs (red); (d) Shows the images of GNPs (left) and GAL-PEG-GNPs (right) detected by TEM. (Zhu. et al., 2015)
At CD BioGlyco, we offer monosaccharide-based nanoparticle production services that use technologies for the development of highly targeted and effective nanoparticles. Our production scale ranges from milligram to gram quantities, ensuring that we meet the needs of both small-scale research projects and large-scale pre-clinical studies. Contact us today to explore how our monosaccharide-based nanoparticle can help advance your research with tailored, high-performance products.
Reference
- Zhu. C.; et al. Synthesis of novel galactose functionalized gold nanoparticles and its radiosensitizing mechanism. Journal of Nanobiotechnology. 2015, 13: 1-11.
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




